|
|
Article: YM Gaining Subsidiary Via Eximias Acquisition.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Canadian firm YM BioSciences Inc. agreed to purchase Eximias Pharmaceutical Corp. in a cash and stock transaction to establish a U.S.-based subsidiary.
Full financial terms were not disclosed, but YM said that at least $25 million of the merger consideration would consist of company shares. In exchange, YM gains Eximias' cash resources of more than $30 million and a portfolio of two clinical-stage cancer drugs.
"It's a good combination of management team, cash and oncology assets," said Gail Schulze, president and CEO of privately held Eximias, adding that more details, including development priorities for the combined company's ...
Related newspaper, magazine, and journal articles:
|
|
Article: YM BIOSCIENCES INC. - Directorate Change.
PR Newswire UK Disclose;
February 12, 2007 ;
700+ words
... ... changes MISSISSAUGA, ON, Feb. 12 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA ... announced that Gail Schulze, President, YM BioSciences, and CEO, YM BioSciences USA, Inc., and John E. Bennett, Vice ...
|
|